Royalty Pharma plc (RPRX) Stock: Price, Forecast & Analyst Target
Royalty Pharma plc (RPRX) — MoonshotScore 74/100 (Strong band), calculated Oct 4, 2026. Price $57.16 (-0.82%), as of the Oct 2, 2026 trading session; market cap $25.3B. Expected results Nov 4, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 30.23× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 4, 2026
Royalty Pharma plc · RPRX · NASDAQ · Healthcare · Medical - Pharmaceuticals
Research dated 2026-09-12: Royalty Pharma buys biopharmaceutical royalty rights and funds drug innovation; it owns cash flow claims on therapies rather than operating as a conventional medicine manufacturer. Its appeal and risk meet at the same point: whether portfolio receipts can support new royalty purchases, dividends, and a debt-heavy capital structure without sustained pressure on liquidity.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Royalty Pharma (RPRX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but a strained balance sheet; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $674M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- Altman Z 2.11 · Piotroski F 6
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 74 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 74 | Strong | |
| 74 | Strong |
The score was 74 in the stored Oct 3, 2026 snapshot and remains 74 in the current publication computed Oct 4, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $57.16 | |
| Change on the day | -0.82% | |
| 52-week range | $35.23–$64.38 | |
| Market capitalisation | $25.3B | |
| Price / earnings (trailing) | 23.71 | |
| Shares traded on the day | 2.23M | |
| Beta (volatility vs the S&P 500) | 0.43 | |
| Dividends per share (last 12 months) | $0.92 | |
| Dividend yield (last 12 months) | 1.62% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We have again raised our guidance, and we expect to continue to deliver another full year of strong financial performance in 2026.
Terrance Coyne · Statement from
Third, we expect to deliver strong, low volatility top line and bottom line growth through 2030 and beyond.
Pablo Legorreta · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Royalty Pharma (RPRX): Bullish Lean
56/100 · BSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the RPRX film — every key number, told as a short cinematic story
~2 min · open the film
What is Royalty Pharma (RPRX), and what does it report?
Short answer · as of
Royalty Pharma purchases economic interests in marketed therapies and development-stage candidates across several therapeutic areas.
Research dated 2026-09-12.
Royalty Pharma purchases economic interests in marketed therapies and development-stage candidates across several therapeutic areas. Its healthcare classification places it alongside pharmaceutical companies, but its revenue comes from royalty assets rather than selling medicines it manufactures.
Financial Royalty Assets generate nearly all reported segment revenue, with Royalty Income, Other contributing a much smaller portion. The income statement records accounting revenue and profit from this portfolio, while operating cash flow captures cash generation; the latest series shows that those measures do not always move together.
What do the latest results show for Royalty Pharma (RPRX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $674M.
Research dated 2026-09-12.
Quarterly revenue advanced from the prior period, yet gross profit, operating profit, net result, and diluted earnings all fell sharply. Research and development expense increased, while selling, general, and administrative expense remained elevated, so the latest top-line gain did not translate into comparable earnings.
Recent earnings releases have shifted from revenue shortfalls to revenue and earnings beats. Management has also raised guidance and continues to describe the longer-run growth profile as strong and low volatility, but that claim sits beside pronounced quarterly profit swings and must be judged separately from estimate comparisons.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $674.14M Jun 30, 2026
- Latest quarter · R&D
- $97.85M Jun 30, 2026
- Latest quarter · SG&A
- $161.89M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $133.00M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $674.14M | $97.85M | $161.89M | $133.00M |
| Mar 31, 2026 | $630.58M | $40.00M | $159.00M | $632.48M |
| Dec 31, 2025 | $621.99M | $51.00M | $164.27M | $388.38M |
| Sep 30, 2025 | $609.29M | $50.50M | $118.73M | $427.16M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $773.00M Aug 5, 2026
- Latest report · revenue estimate
- $758.93M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $773.00M | $758.93M | $1.3200 | $1.2700 |
| May 6, 2026 | $925.00M | $881.69M | $1.3000 | $1.2100 |
| Feb 11, 2026 | $874.00M | $806.96M | $1.4600 | $1.2900 |
| Nov 5, 2025 | $609.29M | $717.38M | $1.1700 | $0.9940 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $674M | $18M | $0.04 (diluted) |
| Q1 FY2026 | $631M | $295M | $0.53 (diluted) |
| Q4 FY2025 | $622M | $214M | $0.50 (diluted) |
| Q3 FY2025 | $609M | $288M | $0.67 (diluted) |
What are the financial strengths and risks for Royalty Pharma (RPRX)?
Short answer
Cash and short-term investments were $836.99M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $686.16M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained substantial throughout the reported window, with no capital expenditure recorded, reflecting the capital-light nature of owning royalty interests. Trailing margins and free-cash-flow yield also point to strong portfolio economics, while recurring dividends return part of that cash to shareholders.
Balance-sheet flexibility is more constrained than cash generation alone suggests. Cash and short-term investments declined materially across the reported window before recovering in the latest period, and total debt remains far above cash and investments. Weaker receipts from underlying therapies or disappointing progress among development-stage candidates would therefore meet continuing financial obligations from a less comfortable liquidity position.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $686.16M Jun 30, 2026
- Previous quarter · operating cash flow
- $760.54M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $686.16M | Not available |
| Mar 31, 2026 | $760.54M | Not available |
| Dec 31, 2025 | $827.15M | Not available |
| Sep 30, 2025 | $702.62M | Not available |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Royalty Pharma (RPRX)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026.
Research dated 2026-09-12.
At the scheduled earnings release, compare reported revenue and earnings with expectations, but give greater weight to whether operating cash flow remains durable and the latest cash recovery continues. Recent estimate beats raised expectations; they did not remove the gap between liquid resources and debt.
Research and development expense, administrative expense, operating profit, and net result deserve close attention after their latest swings. Management’s raised guidance and low-volatility growth claim would gain support from sustained revenue, cash conversion, and earnings progress rather than an isolated favorable comparison with forecasts.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We have again raised our guidance, and we expect to continue to deliver another full year of strong financial performance in 2026.
Terrance Coyne ·
Third, we expect to deliver strong, low volatility top line and bottom line growth through 2030 and beyond.
Pablo Legorreta ·
How does Royalty Pharma compare with its peers?
Short answer
Royalty Pharma's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Conventional biopharmaceutical companies depend on their own research, approvals, manufacturing, and commercialization. Royalty Pharma instead acquires or funds economic rights tied to therapies developed and sold by others, spreading its portfolio across marketed products and development candidates.
The small employee base, absence of reported capital expenditure, and high margins fit a scalable financial-asset model more closely than a laboratory or manufacturing network. Scientific underwriting, partnering, deal selection, and capital allocation are therefore central operating capabilities, while leverage makes the price and funding of royalty acquisitions especially consequential.
| Company | Price | Market value | Score |
|---|---|---|---|
| $115.30 Oct 2, 2026 | $23.4B | 98 5-pillar Oct 4, 2026 | |
| $541.70 Oct 2, 2026 | $23.0B | 97 5-pillar Oct 4, 2026 | |
| $358.07 Oct 2, 2026 | $38.3B | 96 5-pillar Oct 4, 2026 | |
| Royalty Pharma (RPRX) — this page | $57.16 | $25.3B | 74 |
| $34.75 Oct 2, 2026 | $21.3B | 59 5-pillar Oct 4, 2026 | |
| $20.65 Oct 2, 2026 | $1.27B | 56 5-pillar Oct 4, 2026 | |
| $15.51 Oct 2, 2026 | $953M | 56 5-pillar Oct 4, 2026 | |
| $3.22 Oct 2, 2026 | $28.1M | 39 5-pillar Oct 4, 2026 | |
| $2.63 Oct 2, 2026 | $231M | 38 5-pillar Oct 4, 2026 | |
| $1.36 Oct 2, 2026 | $29.1M | 32 5-pillar Oct 4, 2026 | |
| $6.31 Oct 2, 2026 | $25.5M | 27 5-pillar Oct 4, 2026 | |
| $35.72 Oct 2, 2026 | $25.8B | 25 5-pillar Oct 4, 2026 | |
| $22.74 Oct 2, 2026 | $155M | 20 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $57.00 – $66.00
- Consensus target
- $62.67
- Median target
- $65.00
Consensus record · Captured .
Measured against a quoted price of $57.16 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 38
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 16
- Other transactions
- 22
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 83.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 82.9% Prior to period end Jun 30, 2026
- Reporting holders
- 659 Period end Jun 30, 2026
- Previous quarter · holders
- 601 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Morgan Stanley | 42,931,597 |
| Capital International Investors | 35,273,770 |
| Blackrock, INC. | 27,832,977 |
| Fmr LLC | 24,513,814 |
| State Street Corp | 12,338,229 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Royalty Pharma (RPRX)?
- Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
- Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
- Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
Common Questions About RPRX (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why do Financial Royalty Assets dominate Royalty Pharma’s revenue?
Acquired royalty interests, rather than conventional product sales, produce nearly all segment revenue. Therapy-level cash economics and acquisition discipline are therefore more informative than manufacturing volume.
How can Royalty Pharma grow without launching its own medicines?
Royalty receipts can expand as partnered therapies generate more sales or as Royalty Pharma acquires and funds additional rights. Development-stage candidates add potential future royalty streams, though their contribution depends on clinical and commercial progress.
What could break Royalty Pharma’s low-volatility growth claim?
Weak royalty receipts, setbacks among development-stage candidates, or continued swings in expenses and reported profit would challenge that claim. Persistent liquidity pressure alongside substantial debt would make such operating disappointments more consequential.
How should investors reconcile Royalty Pharma’s cash generation with its debt?
Operating cash flow is strong and reported capital expenditure is absent, but debt greatly exceeds cash and investments. That cash generation can support dividends and royalty purchases, yet it does not eliminate the importance of disciplined capital allocation and financial obligations.
What is the RPRX stock price today?
The last price recorded on this page for Royalty Pharma plc (RPRX) is $57.16, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RPRX price target?
The analyst consensus price target for Royalty Pharma plc (RPRX) is $62.67 (range $57.00 to $66.00, median $65.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does RPRX pay a dividend?
Yes. Royalty Pharma plc (RPRX) shows a trailing 12-month dividend yield of 1.62%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Terrance Coyne (Aug 5, 2026): We have again raised our guidance, and we expect to continue to deliver another full year of strong financial performance in 2026. Pablo Legorreta (Aug 5, 2026): Third, we expect to deliver strong, low volatility top line and bottom line growth through 2030 and beyond. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | NEW York, NY | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "110 East 59th Street, New York, NY, 10022, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $57.16 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T01:54:49.418Z. | |
px.change | Change on the day | -0.82% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $25.3B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T01:54:48.133Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.47 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $674M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $35.23–$64.38 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 23.71 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.23M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.43 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Pablo Legorreta | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 100 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $2.29B, net result $619.73M; FY2022 revenue $2.24B, net result $42.83M; FY2023 revenue $2.35B, net result $1.13B; FY2024 revenue $2.26B, net result $858.98M; FY2025 revenue $2.38B, net result $770.95M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Royalty Income, Other $117.04M · Financial Royalty Assets $2.26B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 89.4% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $674.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $97.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $161.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $133.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $630.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $40.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $159.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $632.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $621.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $51.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $164.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $388.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $609.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $50.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $118.73M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $427.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $773.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $758.93M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $1.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $1.2700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_actual | Revenue · reported — report date 2026-05-06 | $925.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_estimated | Revenue · estimate — report date 2026-05-06 | $881.69M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_actual | EPS · reported — report date 2026-05-06 | $1.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_estimated | EPS · estimate — report date 2026-05-06 | $1.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_actual | Revenue · reported — report date 2026-02-11 | $874.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_estimated | Revenue · estimate — report date 2026-02-11 | $806.96M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_actual | EPS · reported — report date 2026-02-11 | $1.4600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_estimated | EPS · estimate — report date 2026-02-11 | $1.2900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $609.29M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $717.38M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | $1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | $0.9940 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $836.99M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $686.16M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $241.92M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $8.96B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.72× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $686.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $760.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $827.15M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $702.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $57.00 – $66.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $62.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 38 transactions · 0 purchases, 16 sales, 22 other transactions · 12 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 83.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 82.9% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 659 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 601 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Morgan Stanley — shares in provider snapshot | 42,931,597 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Capital International Investors — shares in provider snapshot | 35,273,770 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 27,832,977 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fmr LLC — shares in provider snapshot | 24,513,814 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | State Street Corp — shares in provider snapshot | 12,338,229 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-15 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.11 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 30.23× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $836.99M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.92 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.62% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($773.00M) with the recorded estimate ($758.93M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.3200) with the recorded estimate ($1.2700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 74 of 100 · Strong · pillars 92 / 26 / 62 / 45 / 82 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 74 (stored snapshot Oct 3, 2026) → 74 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-06.revenue_actual,earn.history.depth.2026-05-06.revenue_estimated,earn.history.depth.2026-05-06.eps_actual,earn.history.depth.2026-05-06.eps_estimated,earn.history.depth.2026-02-11.revenue_actual,earn.history.depth.2026-02-11.revenue_estimated,earn.history.depth.2026-02-11.eps_actual,earn.history.depth.2026-02-11.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Royalty Income, Other: $117.04M; Financial Royalty Assets: $2.26B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $8.96B; Liquidity basis: cash and short-term investments; Total liabilities: $10.03B; Cash and short-term investments: $836.99M; Cash and investments: $1.08B; Long-term investments: $241.92M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-08-14 | FMP | Financial Modeling Prep (FMP) dividend history |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Pharmaceuticals The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-05 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Most recent periodic reports | 2026-08-05 | OFFICIAL | SEC EDGAR filer submissions | |
| Trailing twelve-month ratio set | Quick ratio: 1.29; Current ratio: 1.29; Debt to equity: 1.31; Net margin: 32.1%; Gross margin: 89.4%; Operating margin: 62.3%; Return on assets: 4.1%; Return on equity: 12.3% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.08B; Cash and short-term investments: $837.00M; Long-term investments: $241.90M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $837.00M; Decline: $927.30M; Opening balance: $1.76B; Average change per period: $132.50M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$8.12B; Total debt: $8.96B; Cash and investments: $837.00M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-04; EPS estimate: $1.18 per share; Revenue estimate: $877.37M The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Employees | Count: 100 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Named officers | CEO: Pablo Legorreta; Officers: James Folmar Reddoch — Title: Executive Vice President of Investments & Chief Scientific Officer, Pay: $3.40M, Born: 1970; Marshall Urist — Title: Head of Research & Investments, Pay: $1.32M, Born: 1976; Greg Butz — Title: Executive Vice President of Partnering & Investments; George Grofik — Title: Senior Vice President and Head of Investor Relations & Communications; Pablo Legorreta — Title: Founder, Chairman of the Board & Chief Executive Officer, Pay: $44.02M, Born: 1963; Terrance Coyne — Title: Executive Vice President & Chief Financial Officer, Pay: $1.32M; Molly Sawaya — Title: Executive Vice President & Head of Human Capital; Christopher Hite — Title: Chairman of Partnering & Investments, Pay: $1.32M, Born: 1967 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
Data provided for informational purposes only.
ETFs that hold RPRX
Funds in our ETF coverage that list RPRX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Eventide High Dividend ETF (ELCV) | 3.10% | |
| Global X - Adaptive U.S. Factor ETF (AUSF) | 2.21% |